New England Professional Planning Group Inc. Takes Position in Pfizer Inc. (NYSE:PFE)

Share on StockTwits

New England Professional Planning Group Inc. purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 233,789 shares of the biopharmaceutical company’s stock, valued at approximately $9,160,000. Pfizer makes up approximately 7.3% of New England Professional Planning Group Inc.’s portfolio, making the stock its 5th largest holding.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Integrated Wealth Concepts LLC lifted its position in Pfizer by 14.2% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 68,060 shares of the biopharmaceutical company’s stock valued at $2,840,000 after purchasing an additional 8,445 shares during the last quarter. Halsey Associates Inc. CT increased its stake in shares of Pfizer by 73.8% in the third quarter. Halsey Associates Inc. CT now owns 44,316 shares of the biopharmaceutical company’s stock valued at $1,592,000 after purchasing an additional 18,822 shares during the period. Whitnell & Co. increased its stake in shares of Pfizer by 390.0% in the third quarter. Whitnell & Co. now owns 50,507 shares of the biopharmaceutical company’s stock valued at $1,815,000 after purchasing an additional 40,200 shares during the period. IHT Wealth Management LLC raised its holdings in shares of Pfizer by 20.5% during the third quarter. IHT Wealth Management LLC now owns 72,126 shares of the biopharmaceutical company’s stock valued at $2,595,000 after buying an additional 12,291 shares during the last quarter. Finally, Altavista Wealth Management Inc. raised its holdings in shares of Pfizer by 7.3% during the third quarter. Altavista Wealth Management Inc. now owns 116,631 shares of the biopharmaceutical company’s stock valued at $4,191,000 after buying an additional 7,963 shares during the last quarter. Hedge funds and other institutional investors own 70.21% of the company’s stock.

NYSE PFE opened at $40.67 on Thursday. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $44.56. The firm has a market capitalization of $221.75 billion, a PE ratio of 13.56, a P/E/G ratio of 4.24 and a beta of 0.65. The company’s 50 day simple moving average is $38.90 and its 200 day simple moving average is $38.18. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.90 and a quick ratio of 0.68.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.13. The firm had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $12.37 billion. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The firm’s revenue for the quarter was down 4.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.78 earnings per share. Sell-side analysts anticipate that Pfizer Inc. will post 2.97 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be paid a $0.38 dividend. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.74%. The ex-dividend date of this dividend is Thursday, January 30th. This is an increase from Pfizer’s previous quarterly dividend of $0.36. Pfizer’s payout ratio is currently 48.00%.

Several brokerages have recently issued reports on PFE. ValuEngine upgraded Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Credit Suisse Group reaffirmed a “hold” rating and set a $41.30 target price on shares of Pfizer in a research note on Wednesday, November 6th. Bank of America started coverage on Pfizer in a research report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price target for the company. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research report on Tuesday, October 1st. Finally, Royal Bank of Canada initiated coverage on Pfizer in a research note on Monday, January 6th. They issued an “outperform” rating and a $46.00 price target for the company. Nine investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and a consensus target price of $43.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Purposes and Functions of the Federal Reserve

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.